Tencent Posts Earnings Beat as AI Buoys Game, Ad Businesses
The WeChat operator, China's largest company by market capitalization, said Wednesday that second-quarter net profit rose 17% from a year earlier to 55.63 billion yuan, equivalent to $7.75 billion. That beat the 51.095 billion yuan estimated by analysts in a FactSet poll.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
e.l.f. Beauty, Inc. (ELF)'s Selling In Dollar General Because 'It's The Last One,' Says Jim Cramer
We recently published . e.l.f. Beauty, Inc. (NYSE:ELF) is one of the stocks Jim Cramer recently discussed. e.l.f. Beauty, Inc. (NYSE:ELF) is a firm that can't seem to catch a break. After struggling in a tough cosmetics market in 2024, the firm has continued to struggle in 2025 as investors fret about its ability to weather the inflationary storm from tariffs. e.l.f. Beauty, Inc. (NYSE:ELF)'s affordable cosmetics depend on its Chinese supply chain, making the tariff concerns self-explanatory. Cramer remarked on the firm selling cosmetics in Dollar General: '[On why ELF was selling its products in Dollar General] Because it's the last one. The shorts are telling me, not that I listen to the shorts, but the shorts are saying, what's after Dollar General? Is there anything after?' Copyright: antonioguillem / 123RF Stock Photo Here are his previous thoughts about e.l.f. Beauty, Inc. (NYSE:ELF): 'What the heck just happened to e.l.f. Beauty? I mean, the last time we got results from this low-cost cosmetics and skincare brand and the stock got eviscerated today, down nearly 10%. You know, we've long championed this one. It's been a great growth stock over the last few years, largely because it offers its customers quality merchandise at incredibly affordable prices. Unfortunately, it can charge low prices because it makes most of its goods in China, which means most of e.l.f.'s products are about to become more expensive. So last night, even though e.l.f. delivered a nice top and bottom line beat, management declined to issue a full year forecast because they really have no idea how the tariff situation's… going to play out. However, the limited guidance they gave did suggest that their margins are going to take a real hit… Maybe that's why things got, well, just awry.' While we acknowledge the potential of ELF as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
28 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Cerence Inc. (CRNC) Might Be A Hidden Gem, Says Jim Cramer
We recently published . Cerence Inc. (NASDAQ:CRNC) is one of the stocks Jim Cramer recently discussed. Cerence Inc. (NASDAQ:CRNC) is a software company that caters to the needs of the transportation industry. Its shares have gained 60% year-to-date and gained an unbelievable 45% in August. Cerence Inc. (NASDAQ:CRNC) is benefiting from the AI wave through having landed major deals, such as a partnership with Mercedes-Benz. Cramer discussed the firm in the context of it being an outlier that could be interesting in the AI era: 'I'm doing a piece about Cerence tonight. People are going to want to find out what I'm saying there. There's a lot of technology away from these big companies that is better than the big companies.' Copyright: audioundwerbung / 123RF Stock Photo Here are Cramer's previous thoughts about Cerence Inc. (NASDAQ:CRNC): 'I like Cerence, and I also happen to like Brian Krzanich, the CEO. I am partial. They make money. I think you've got a winner. I was actually trying to figure out whether I could justify doing a piece on it because it's not that expensive. Cerence is a winner, and Brian's always welcome on the show, as we know.' While we acknowledge the potential of CRNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
